P3 Health Partners Shares Soar After Lifting FY Adj Ebitda Outlook

Dow Jones05-15

By Christopher Kuo

 

P3 Health Partners shares soared after the company swung to a first-quarter profit and raised its full-year outlook for adjusted earnings before interest, taxes, depreciation and amortization.

Shares of the health management company climbed 43% to $5.80 after hours. The stock closed up 13% during the regular session.

The company on Thursday posted a first-quarter profit of $1.2 million, or 32 cents a share, compared with a loss of $20.5 million, or $6.28 a share, a year earlier.

The company also raised its full-year outlook for adjusted Ebitda. It expects adjusted Ebitda of $20 million to $60 million in fiscal 2026, compared with previous guidance of a loss of $20 million to a profit of $40 million.

"Q1 represents a meaningful turning point for the business. The $26 million of adjusted Ebitda we delivered this quarter reflects the cumulative impact of two years of deliberate work, including contract restructuring, network concentration, and operational redesign," said Chief Executive Aric Coffman.

The company expects full-year revenue between $1.5 billion to $1.65 billion, compared with prior guidance of $1.5 billion to $1.7 billion.

Operating revenue rose to $386.4 million from $373.2 million a year earlier.

 

Write to Christopher Kuo at chris.kuo@wsj.com

 

(END) Dow Jones Newswires

May 14, 2026 18:28 ET (22:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment